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ABSTRACT 
 
Background: Acute renal failure is a frequent complication of systemic 
inflammatory response syndrome (SIRS) and sepsis. Hydroxyethyl starches 
(HES) are widely used in the treatment of such patients. However, the effect of 
HES on renal function during sepsis remains controversial. This in vitro study has 
been performed to assess possible effects of HES 130/0.42 and HES 200/0.5 on 
activated proximal tubular epithelial cells. 
Materials and Methods: Monolayers of HK-2 cells (a cell line of immortalized 
human proximal tubular epithelial) were stimulated with tumor necrosis factor 
alpha (TNF-α) (control with phosphate-buffered saline, PBS) in the presence or 
absence of HES 130/0.42 or 200/0.5 to mimic a septic condition requiring fluid 
replacement. After 4, 10, and 18 h of incubation monocyte chemoattractant 
protein-1 (MCP-1), a key chemoattractant for neutrophils and macrophages, was 
determined. Colorimetric viability- and cytotoxicity assays as well as experiments 
with FITC-labeled HES preparations were performed. 
Results: MCP-1 expression was enhanced by 100% (p< 0.01) upon TNF-α 
exposure. In the presence of 2% and 4% HES 200/0.5 during a stimulation time 
of 10 h and 18 h, MCP-1 concentration was decreased between 22% and 64% 
(p< 0.05). TNF-α stimulation resulted in a significant decrease of viability by 30% 
(p< 0.01), while viability decreased by only 16% in co-incubation with HES 
130/0.42 (p< 0.05), and remained even unaffected in the presence of HES 
200/0.5 (p< 0.01). Cell death rate of TNF-α-exposed cells increased by 9%. In 
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co-incubation with HES 130/0.42 or HES 200/0.5 cell death rate increased by 
only 1% (p< 0.01) and 4% (p< 0.01), respectively. 
Discussion and Conclusion: Data of this in vitro study show that in the 
presence of both HES products an attenuation of cell injury is measured in 
proximal tubular epithelial cells upon inflammatory stimulation. If these findings 
are of beneficial or proinflammatory character has further to be investigated. 
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INTRODUCTION 
 
Systemic inflammatory response syndrome (SIRS) and sepsis with multiple 
organ failure remain leading causes of death in intensive care units, despite 
substantial research in this field over several decades 1. Pathophysiological 
changes in patients with SIRS or sepsis are characterized by enhanced 
expression of inflammatory mediators, accumulation of neutrophils and increased 
vascular permeability with capillary leakage, which results in interstitial edema 
formation, decreased intravascular volume and poor perfusion of organs. 
Adequate fluid management is therefore a key issue in these patients. Clinically, 
colloids are frequently used for volume replacement when attempting to maintain 
or improve tissue perfusion in patients experiencing infection, sepsis, trauma, 
shock, or surgical stress 2-4. Compared to cristalloids colloids have the advantage 
of augmenting colloid oncotic pressure and minimizing edema formation, 
therefore improving oxygen delivery and organ function 5. 
Hydroxyethyl starches (HES) are among the most widely used compounds 
because their volume-expanding effect is both large and long-lasting. There has 
been extensive research on general effectiveness and safety of colloid 
administration in septic patients 2,6. With a special focus on the kidneys both 
deleterious and protective effects of HES compounds are known 7. These 
experiences, however, are based on clinical observations and not on basic 
research data 8. 
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Aim of this study was the evaluation of the effect of HES 130/0.42 and 
HES 200/0.5 on injured human tubular epithelial cells, possibly representing the 
situation in a septic patient receiving fluid resuscitation with HES. Inflammatory 
response (production of monocyte chemoattractant protein-1, MCP-1), cell 
viability and colloid-induced cell death was determined. Additionally, fluorescence 
labeled-HES was localized in injured cells. We hypothesized that both HES 
products have proinflammatory characteristics on already injured tubular 
epithelial cells. Differences regarding effects of these two preparations are not 
expected. 
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MATERIAL AND METHODS 
 
Cell Culture 
HK-2 cells, a human proximal tubule cell line, were used 9. Cells were cultivated 
under standard conditions, including temperature (37°C), CO2 concentration 
(5%), and humidity (95%). 
Cultivation was performed in 24-well plates (Corning Inc., NY, USA), in 96-
well cell plates (NunclonTMSurface, NUNC, Wiesbaden, Germany), or in 96-strip 
well plates (Costar®, Corning Inc.). Dulbecco's Modified Eagle Medium (DMEM, 
Invitrogen, Basel, Switzerland), with 10% fetal bovine serum (FBS, Invitrogen, 
Basel, Switzerland), 1% Hepes 1 M (Life Technologies, Basel, Switzerland), 1% 
Penicillin-Streptomycin (Life Technologies, Basel, Switzerland) and 0.1 mg 
epidermal growth factor (Invitrogen, Basel Switzerland) was used as medium for 
cultivation. 
Cells were used with a 90% confluence. 12 h before experiments were 
started medium was changed to DMEM/1% FBS with 1% sodium pyruvate 
(Invitrogen, Basel, Switzerland).  
 
Experimental Design 
Inflammation of HK-2 cells was induced by recombinant tumor necrosis factor 
alpha (recombinant human TNF-α, BD Pharmingen, Basel, Switzerland) 
concentrated  between 0.1 and 10 ng/ml. HES 130/0.42 and HES 200/0.5 were 
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provided by BBraun, Switzerland. Experiments were performed in four different 
groups: control (co), HES, TNF-α (TNF), TNF/HES. 
After 2 h of “pre-stimulation” medium of control cells (Co) was changed, 
while HES cells (HES) were given new medium with HES. TNF-α stimulation was 
renewed as well after an initial stimulation of 2 h (TNF) or, in the TNF/HES group 
medium containing TNF-α and HES was replaced. Supernatants and/or cells 
were collected after 4, 10 or 18 h of stimulation, and cytotoxicity assays and/or 
viability tests were performed. Supernatants were aliquoted and frozen at -20°C. 
 
ELISA (Enzyme-linked immunosorbent assay) 
MCP-1 released from HK-2 cells into culture media were determined by enzyme-
linked immunosorbent assay (ELISA). Sandwich ELISA was performed according 
to the manufacturer’s protocol assessing human MCP-1 (R&D Systems Europe 
Ltd.). The detection range for MCP-1 was 0 - 500 pg/ml.  
 
Cell viability assay 
The MTT-assay is a well-known and acknowledged method to measure cell 
viability in vitro 10. The method is based on the reduction of the yellow 
tetrazoliumsalt 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide 
(MTT) into purple formazan crystals by mitochondrial dehydrogenases. 
Dehydrogenases are active in living cells only. Conversion of MTT is therefore 
directly related to cell viability. 
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MTT was purchased from Sigma (Buchs, Switzerland). A stock solution 
was prepared diluting 5 mg of MTT in 1 ml PBS. MTT stock solution was added 4 
h before end of each time course. Plates were incubated for 4 h at 37°C and 
supernatants were removed thereafter. Reduction of MTT was stopped by adding 
MTT solubilization solution from Sigma (Buchs, Switzerland). Data were collected 
spectrophotometrically using a standard 96-well plate reader (Labsystems 
Multiskan RC-Elisa reader, BioConcept, Allschwil, Switzerland, wavelength of 
570nm). 
 
LDH-Assay 
Cell death rate (cytotoxicity) was determined using a nonradioactive standard 
lactate dehydrogenase (LDH) assay (Promega, Madison, WI, USA). We used the 
LDH assay to measure membrane integrity of the HK-2 cells by quantitatively 
measuring lactate dehydrogenase (LDH), a stable cytosolic enzyme, that is 
released upon cell lysis. 
 Cells were cultivated in 96-well-plates. At the end of each time course 
cells of some wells of each group were lysed with 10 µl 1% Triton X-100 
(Sigma®) to determine total LDH of the cells. 50 µl of supernatants of each well 
were transferred to a new 96-well plate. 50 µl of the LDH substrate reagent were 
added to each well already containing 50 µl of the transferred supernatant. The 
plate was incubated for 30 min a room temperature and kept away from light. 
Reaction was stopped by 50 µl of 1 M acetic acid. Absorbance was read at a 
wavelength of 492 nm.  
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Labeling of HES with Fluorescein Isothiocyanat (FITC) 
Preperations were made following a slightly modified method as described by 
DeBelder and Granath (1973): 1.19 g HES (dried at 70°C over P2O5 in oil pump 
vacuum) was added to 15 ml dimethylsulfoxide (DMSO, Sigma, Switzerland) and 
heated at 95°C. After HES was fully dissolved 125 mg fluorescein isothiocyanate 
(FITC, Fluka, Switzerland) was added. After 6 h the solution was cooled to room 
temperature and added to 100 ml ethanol, to precipitate the labeled HES. To 
eliminate any free unreacted FITC, the precipitated HES was dissolved in 20 ml 
deionized water and dialysed against water for five days. The exclusion volume 
of the membrane (Spectrum Laboratories, Inc., Ca, USA) was 3.5 g/mol. Final 
isolation of the labeled HES was done by lyophilisation. FITC-labeled HES was 
then resuspended in 0.9% NaCl to obtain the original concentration of 6%. 
 
Cellular HES Uptake 
HK-2 cells were cultured on LabTek chamber slides as described above. 
Inflammation was induced by stimulation with TNF-α (10 ng/ml). After 2 h 
medium was changed and experimental groups were set up as described for 18 
h with 4% FITC-HES. Cells were washed with PBS, fixed with 3% 
paraformaldehyde in PBS for 2 min, washed again and a 4,6-diamidino-2-
phenylindole-staining (DAPI) was performed. After a final wash step, cover slips 
were mounted by using Dako-glycerol containing 2.5%-diazybicyclo-(2.2.2)-
octane (Sigma-Aldrich). Conventional fluorescent images were taken by using an 
 12
inverted microscope (Eclipse TE 300/200; Nikon, Germany) equipped with a 60x 
oil immersion objective, confocal images were taken by a Leica TCS SP 5 UV 
CLSM (Wetzlar, Germany) laser scan microscope equipped with a 63x oil 
immersion objective.  
 
Statistics 
All experiments were performed at least five times with 5 data points for each 
group. Each data point in the graphs represents mean +/- standard error of the 
mean (SEM). Analysis of variance (ANOVA) was performed to assess the 
statistical significance of differences. Differences were considered significant 
when p< 0.05. 
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RESULTS 
 
MCP-1-Expression 
HES 130/0.42 
To evaluate expression of MCP-1 upon stimulation, HK-2 cells were incubated 
with recombinant TNF-α (control with PBS). After 2 h of stimulation cells were co-
incubated with 1% HES 130/0.42 or PBS. Incubation with 1% HES 130/0.42 did 
not alter MCP-1 expression. MCP-1 significantly increased from 14±1.6 pg/ml to 
28±1.8 pg/ml upon TNF-α stimulation (p< 0.05) (Fig. 1A). Treatment with 1% 
HES 130/0.42 in the presence of TNF-α did not change MCP-1 expression. 
Increasing HES 130/0.42 concentrations to 2% and 4% did not influence MCP-1 
expression irrespective of the presence or absence of TNF-α (Fig. 1A). 
 Similar data were found, stimulating HK-2 cells with TNF-α for 10 h, 
adding HES 130/0.42 2 h after initiating TNF-α incubation. While MCP-1 
concentration was changed from 16±1.3 pg/ml to 35±3.5 pg/ml upon TNF-α 
stimulation (p< 0.05), 1%, 2%, and 4% HES 130/0.42 did not have any impact on 
MCP-1 production in the presence of TNF-α (Fig. 1B). 
 18 h stimulation with TNF-α increased MCP-1 concentration from 14±1.2 
pg/ml to 28±1.0 pg/ml (p< 0.01), while 1%, 2%, and 4% HES 130/0.42 did not 
alter TNF-α-stimulated MCP-1 expression (Fig. 1C). 
 To evaluate the exact impact of TNF-α stimulation, we altered TNF-α 
concentrations from 0.1 to 1, 5, and 10 ng/ml TNF-α. Co-incubation with 4% HES 
130/0.42 and TNF-α in different concentrations, however, did not lead to 
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significant changes of MCP-1 expression in comparison to the TNF-α group (Fig. 
2A).  
 
HES 200/0.5 
The effect of HES 130/0.42 was compared with HES 200/0.5. The same 
experiments as mentioned above were performed with HES 200/0.5.  
 Again, MCP-1 significantly increased from 4±1.5 pg/ml to 33±3.8 pg/ml 
upon TNF-α stimulation (p< 0.05) (Fig. 3A). Interestingly, while a 4 h co-
incubation with 1% and 2% HES 200/0.5 did not alter expression of MCP-1 in the 
presence of TNF-α, 4% HES 200/0.5 significantly decreased MCP-1 expression 
from 29±2.7 pg/ml to 17±3.2 pg/ml (p< 0.05) (Fig. 3A). 
 The 10 h time course showed the following change of MCP-1 expression: 
while 1% HES 200/0.5 did not influence TNF-α-induced production of MCP-1, 2% 
and 4% decreased MCP-1 from 33±3.5 pg/ml to 20±1.2 pg/ml (p< 0.05) and from 
31±1.3 pg/ml to 25±0.6 pg/ml (p< 0.05), respectively (Fig. 3B).  
 The 18 h TNF-α stimulation with 1% HES 200/0.5 did not decrease MCP -
1 expression as compared with the TNF-α exposure alone, but with 2% HES 
200/0.5 MCP-1 expression decreased from 25±0.9 pg/ml to 17±2.5 pg/ml (p< 
0.05), and with 4% HES 200/0.5 from 29±3.0 pg/ml to 10±1.1 pg/ml (p< 0.05) 
(Fig. 3C). 
 TNF-α concentrations of 0.1 ng/ml, 1 ng/ml, 5 ng/ml, and 10 ng/ml were 
used for stimulations for 18 h. While TNF-α concentrations of 0.1 and 1 ng/ml in 
co-incubation with HES 130/0.42 did not show any differences in MCP-1 
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expression compared to TNF-α alone, TNF-α concentrations of 5 or 10 ng/ml in 
co-incubation with HES 200/0.5 induced less MCP-1 expression than with TNF-α 
alone (5 ng/ml TNF-α: 25±2.6 pg/ml vs. 14±0.9 pg/ml (p< 0.05); 10 ng/ml TNF-α: 
29±3.2 pg/ml vs. 14±2.2 pg/ml (p< 0.05) (Fig. 2B). 
 
Determination of Cell Viability 
HES 130/0.42 
Another goal of this study was to evaluate cell viability upon TNF-α stimulation 
with and without co-incubation with 4% HES 130/0.42. A TNF-α stimulation of 18 
h was chosen with varying TNF-α concentrations between 0.1, 1, 5, and 10 
ng/ml. Viability decreased by 22% upon stimulation with 0.1 ng/ml TNF-α (p< 
0.05) (Fig. 4A). In the presence of 4% HES 130/0.42, viability decreased only by 
7% (p< 0.05). With 1 ng/ml TNF-α stimulation, viability decreased by 22% (p< 
0.05), in the presence of 4% HES 130/0.42, however, only 3% (p< 0.05). With 5 
ng/ml TNF-α stimulation, viability decreased by 25% (p< 0.05) and by 7% (p< 
0.05) in the presence of 4% HES 130/0.42. With 10 ng/ml TNF-α stimulation 
finally, viability decreased by 26% (p< 0.05) and by 15% (p< 0.05) in the 
presence of 4% HES 130/0.42 (Fig. 4A). 
 
HES 200/0.5 
Experiments were repeated, co-incubating HK-2 cells with 4% HES 200/0.5 in 
the presence of 0.1, 1, 5, and 10 ng/ml TNF-α. TNF-α- induced decrease of cell 
viability was 20% upon stimulation with 0.1 ng/ml (p< 0.05), 25% with 1 ng/ml (p< 
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0.05), and 36% with 5 ng/ml (p< 0.05). Upon stimulation with 10 ng/ml cell 
viability was impaired by 37 % (p< 0.05). A stimulation with 0.1 ng/ml TNF-α in 
co-incubation with HES 200/0.5 decreased viability by only 10% (p< 0.05), with 1 
ng/ml viability remained unchanged in comparison to control cells (p< 0.05), with 
5 ng/ml by 16% (p< 0.05), and with TNF-α 10 ng/ml again no change of viability 
was observed compared to control cells (p< 0.05) (p values in comparison to 
TNF-α stimulation) (Fig. 4B). 
 
Determination of Cytotoxicity 
HES 130/0.42 
The same experiments were repeated and cytotoxicity was determined. While 
0.1 ng/ml TNF-α stimulation did not increase HK-2 cell toxicity compared to PBS-
exposed cells, 1, 5, and 10 ng/ml induced cytotoxicity, which was significantly 
higher (6%, 5%, and 7%, respectively, p< 0.05) in comparison to control cells 
(Fig. 5A). Co-incubation with HES 130/0.42 led to no increase of cytotoxicity in 
the presence of 5 ng/ml TNF-α (p< 0.05) and to an attenuation of cytotoxicity of 
4% in the presence of 10 ng/ml TNF-α (p< 0.05) (p values in comparison to TNF-
α stimulation).  
 
HES 200/0.5 
Incubating HK-2 cells with different concentrations of TNF-α and co-incubating 
them with 4% HES 200/0.5 gave similar results as with HES 130/0.42. HES 
200/0.5 led to an attenuated increase of cytotoxicity: 1% in the presence of 1 
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ng/ml TNF-α, 2% with 5 ng/ml TNF-α, and 4% with 10 ng/ml TNF-α (p< 0.05) (p 
values in comparison to TNF-α stimulation) (Fig. 5B).  
 
Cellular Uptake of FITC-labeled HES  
Cellular Uptake of FITC-labeled HES was shown for both HES 130/0.42 and 
HES 200/0.5. However, a visible difference in the quantity of HES uptake 
regarding both HES compounds was observed when comparing TNF-α 
stimulated cells with unstimulated cells (Fig. 6A-D). To demonstrate an 
intracellular uptake confocal microscopy was performed. Three-dimensional 
reproduction showed a clear intracellular accumulation of HES-FITC (Fig. 7A,B).   
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DISCUSSION 
 
HES has been shown to be beneficial in several inflammatory contexts in vitro 
and in vivo by attenuating chemotaxis of white blood cells through endothelial 
cells, downregulating inflammatory mediators in blood during sepsis, and 
improving pulmonary function during endotoxemia 11-13. Additionally, recent data 
suggests that in sepsis HES may decrease production of hepatic inflammatory 
mediators 14. 
Acute renal failure (ARF) is a common complication of severe sepsis and 
septic shock 15,16. Correction of volume depletion is crucial to the prevention of 
acute tubular necrosis. Data exists that colloids may show advantages in 
maintaining kidney function in comparison to crystalloid volume replacement 17. 
The choice of administered colloid, however, might affect renal function in 
severely ill patients. Clinical trials pointed out the negative effect of HES 200 on 
kidney function in sepsis 18,19. Possible deleterious renal effects of HES have 
been described even in the absence of an inflammatory situation. In two patients 
receiving HES 200/0.5 deterioration of pre-existing renal impairment was 
reported 20. Two cases of ARF were reported after administration of HES 450/0.7 
21. Renal insufficiency with biopsy-proven osmotic nephrosis-like lesions was 
attributed in further cases 22,23. Evidence has been reported that the use of HES 
in brain dead organ donors may be associated with osmotic-like lesions of both 
the proximal and the distal renal tubules 24,25. These data are supported by 
another study including 69 kidney transplants from brain-dead donors, which 
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showed that the need of hemodialysis or hemodiafiltration was significantly 
higher in the group receiving HES 200/0.62 plus gelatin than in the gelatin group 
24. In another controlled study, urinary output of 24 renal transplant patients was 
lower in the group receiving HES than no HES 26.  
No data exist so far evaluating the impact of HES products on inflamed 
tubular epithelial cells in vitro. We therefore evaluated some aspects of the 
inflammatory response of human tubular epithelial cells upon stimulation with 
TNF-α and the co-incubation with HES 130/0.42 or 200/0.5. 
In a first experimental setup the inflammatory response was evaluated 
regarding expression of MCP-1. This chemokine was primarily chosen as the 
main molecular target, playing a pivotal role not only in monocyte but also in 
polymorphonuclear cell (PMN) recruitment in various experimental systems 27-31. 
Interestingly, HES 130/0.42 did not have an impact on MCP-1 expression in 
combination with TNF-α stimulation. HES 200/0.5, however, attenuated TNF-α -
induced MCP-1 production. This observation points towards a certain difference 
between HES 130/0.42 and HES 200/0.5 regarding interference with the 
inflammatory cascade. If decreased expression of MCP-1 is beneficial or harmful 
has further to be evaluated, but might rather be explained as an attenuation of 
inflammation. Whether these observed effects are merely due to the fact that 
HES molecules cover the cell surface and thereby anticipate TNF-α interaction 
with the receptor, or can be attributed to endocytosis and some yet unknown 
intracellular target will be an issue of further investigations. 
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Previous in vitro studies on endothelial cell activation suggested a 
possible beneficial role of HES in the inhibition of endothelial cell activation, 
preventing neutrophil adhesion upon stimulation with endotoxin  Another study 
found that HES treatment of PMNs significantly altered tethering to and 
transmigration through stimulated cultured human endothelial cell monolayers 32. 
Results from an in vitro study, performed with human microvascular endothelial 
cells under 2% oxygen for 48 h indicate that hypoxia-induced increases in 
vascular leakage and acute inflammation are attenuated by HES treatment 33. 
Similar results were also achieved in several animals models, showing that HES 
had an anti-inflammatory effect through suppression of inflammatory mediators. 
Feng et al. induced sepsis by performing cecal ligation und puncture (CLP) 34. 
Animals were randomly assigned to receive saline or HES 130/0.4. Pulmonary 
inflammation was elucidated. Resuscitation with HES 130/0.4 significantly 
attenuated the CLP-induced increase of cytokine- and chemokine levels and 
recruitment of neutrophils. This theory was also confirmed by Lv et al 14. In the 
CLP model, HES showed beneficial effects in pulmonary injury through 
downregulation of inflammatory mediators and suppression of NF-kappaB. 
Beside the inflammatory response we were also interested in the effect of 
both HES products on cell viability. Increased viability of tubular epithelial cells in 
the presence of HES 130/0.42 and 200/0.5 upon stimulation with TNF-α was 
observed. Both HES preparations restored the mitochondrial activity, which was 
impaired by exposure to TNF-α. This is an interesting observation and was not 
hypothesized. The mechanism of HES-induced cell protection is not clear and 
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has further to be investigated. Similar observations were made focusing on cell 
death. While incubation with TNF-α showed a minor cytotoxicity, measured by 
the release of LDH upon rupture of the cell membrane, HES 130/0.42 as well as 
HES 200/0.5 prevented it. Also in this case, no difference between HES 130/0.42 
and HES 200/0.5 was observed. Interestingly, these data underline a certain 
HES-induced protection. 
Another important goal of this study was to evaluate if tubular epithelial 
cells ingest HES as observed in other cells such as monocytes, keratinocytes, or 
perivascular histiocytes 35,36. Experiments with FITC-labeled HES preparations 
were performed. They indicate an increased cellular uptake of FITC-HES by 
TNF-α stimulated cells in comparison to unstimulated cells. These data would 
support the theory, that HES, once intracellular accumulated, could interfere with 
intracellular pathways. 
 In summary, our in vitro findings of HES-exposed TNF-α-injured tubular 
epithelial cells suggest that the application of HES has potential to attenuate the 
degree of injury. Well-designed in vivo studies, followed by more clinical studies 
are needed to transfer these results of basic research into clinical practice. 
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FIGURE LEGEND 
 
Fig. 1A:  
HES 130/0.42 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 130/0.42 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 4 h. MCP-1 
ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments.  
 
Fig. 1B: 
HES 130/0.42 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 130/0.42 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 10 h. MCP-
1 ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments.  
 
Fig. 1C:  
HES 130/0.42 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 130/0.42 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 18 h. MCP-
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1 ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments.  
 
Fig. 2A:  
HES 200/0.5 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 200/0.5 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 4 h. MCP-1 
ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments.  
P < 0.05 between TNF and TNF/HES group.  
 
Fig. 2B:  
HES 200/0.5 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 200/0.5 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 10 h. MCP-1 
ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments.  
P < 0.05 between TNF and TNF/HES group.  
 
Fig. 2C:  
HES 200/0.5 1%, 2%, or 4% administration and expression of monocyte 
chemoattractant protein-1 (MCP-1). Confluent cell layers were pre-treated with 
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TNF-α 10 ng/ml (or PBS for control) for 2 h, followed by a co-incubation of cells 
with HES 200/0.5 1%, 2%, or 4% with or without TNF-α 10 ng/ml for 18 h. MCP-1 
ELISA was performed with supernatants. Values are mean ± SEM from 5 
experiments. 
P < 0.05 between TNF and TNF/HES group.  
 
Fig. 3A:  
HES 130/0.42 4% administration and expression of monocyte chemoattractant 
protein-1 (MCP-1). Confluent cell layers were pre-treated with TNF-α 
concentrated 0.1, 1, 5, or 10 ng/ml (or PBS for control) for 2 h, followed by a co-
incubation of cells with HES 130/0.42 4% with or without TNF-α 0.1, 1, 5, or 10 
ng/ml for 18 h. MCP-1 ELISA was performed with supernatants. Values are 
mean ± SEM from 5 experiments.  
 
Fig. 3B:  
HES 200/0.5 4% administration and expression of monocyte chemoattractant 
protein-1 (MCP-1). Confluent cell layers were pre-treated with TNF-α 
concentrated 0.1, 1, 5, or 10 ng/ml (or PBS for control) for 2 h, followed by a co-
incubation of cells with HES 200/0.5 4% with or without TNF-α 0.1, 1, 5, or 10 
ng/ml for 18 h. MCP-1 ELISA was performed with supernatants. Values are 
mean ± SEM from 5 experiments.  
P < 0.05 between TNF and TNF/HES group.  
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Fig. 4A:  
HES 130/0.42 4% administration and cell viability. Confluent cell layers were pre-
treated with TNF-α concentrated 0.1, 1, 5, or 10 ng/ml (or PBS for control) for 2 h 
followed by a co-incubation of cells with HES 130/0.42 4% with or without TNF-α 
0.1, 1, 5, or 10 ng/ml for 18 h. Values are mean ± SEM from 5 experiments.   
P < 0.05 between TNFα and HES-TNFα, and between TNFα and HES.  
 
Fig. 4B:  
HES 200/0.5 4% administration and cell viability. Confluent cell layers were pre-
treated with TNF-α concentrated 0.1, 1, 5, or 10 ng/ml (or PBS for control) for 2 h 
followed by a co-incubation of cells with HES 200/0.5 4% with or without TNF-α 
0.1, 1, 5, or 10 ng/ml for 18 h. Values are mean ± SEM from 5 experiments.   
P < 0.05 between TNF and control group, and between TNF and TNF/HES.  
 
Fig. 5A:  
HES 130/0.42 4% administration and cell death. Confluent cell layers were pre-
treated with TNF-α concentrated 0.1, 1, 5, and 10 ng/ml (or PBS for control) for 2 
h, followed by a co-incubation of cells with HES 130/0.42 4% with or without 
TNF-α 0.1, 1, 5, or 10 ng/ml for 18 h. Values are mean ± SEM from 5 
experiments.   
P < 0.05 between TNF and control group, and between TNF and TNF/HES.  
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Fig. 5B: 
HES 200/0.5 4% administration and cell death. Confluent cell layers were pre-
treated with TNF-α concentrated 0.1, 1, 5, and 10 ng/ml (or PBS for control) for 2 
h, followed by a co-incubation of cells with HES 200/0.5 4% with or without TNF-
α 0.1, 1, 5, or 10 ng/ml for 18 h. Values are mean ± SEM from 5 experiments.   
P < 0.05 between TNF and control group, and between TNF and TNF/HES.  
 
Fig. 6A-D: 
A. Stimulation of HK-2 cells with phosphate-buffered saline for 2 h, followed by 
exposure to 4% HES-FITC 130/0.42 (green) for 18 h. B. Exposure of HK-2 cells 
to TNF-α for 2 h, followed by a stimulation with TNF-α for 18 h in the presence of 
4% HES-FITC 130/0.42 (green). C. Stimulation of HK-2 cells with phosphate-
buffered saline for 2 h, followed by exposure to 4% HES-FITC 200/0.5 (green) for 
18 h. D. Exposure of HK-2 cells to TNF-α for 2 h, followed by a stimulation with 
TNF-α for 18 h in the presence of 4% HES-FITC 200/0.5 (green). Blue DAPI 
staining represents nuclei of the cells. 
 
Fig. 7A,B: 
Confocal microscopy showing cellular uptake of 4% HES-FITC (green). 
A. Exposure of HK-2 cells to TNF-α for 2 h, followed by a stimulation with TNF-α 
for 18 h in the presence of 4% HES-FITC 130/0.42 (green). B. Exposure of HK-2 
cells to TNF-α for 2 h, followed by a stimulation with TNF-α for 18 h in the 
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presence of 4% HES-FITC 200/0.5 (green). Blue DAPI staining represents nuclei 
of the cells. 
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Fig. 1A,B,C: 
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Fig. 2A,B,C: 
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Fig. 3A,B: 
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Fig. 4A,B: 
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Fig. 5A,B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42
Fig. 6A-D: 
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